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In treatment of renal ce both cmplte (CRs) and partial rmis (PRs) have
been obtained using recombinant (r) inteeron alpha (IFN-a), with response rates ranging from 0 to 31%
(mean 16%). rIFN-7 is a potent t imu lating agent, but the clinil expenence of its use is limited and
results are confiicting. In a phase n study with combination of rIFN-a, (Boehringer and
rIFN-y (Genentechsppled by Boehring I lm) in 31 eligible patients, a response rate of 25% was
recorded. Based on this observation a lmised phase m study was initiated to invesgate the possible
advantage of the addition rIFN-y to rFN-a, treatnenL Treatment of rFN-%,.
30 pg m-2 = 10 x 10' IU m-2 sc. twice weeky in arm A and the same dose of rIFN-a combined with rIFN-j
100 pg m-2 = 2 x 10' IU m-2 in arm B. Eligbility criteria includ documented pro on of disase;
patients with bone lesions only and overt central nervous system mastases ded Between November
1988 and September 1990, 102 patients we entered into the study. An interm analysis showed a response in
7/53 (13%) patients (two CRs and five PRs) in the rIFN-ax monotherapy arm and in 2/45 (4%) (one CR and
one PR) patients in the combination arm. This differene was not statisl sigifiant (P = 0.17). The
probability of missing an eventual 10/!. advantage for the combiation is 0.001. The numbers are in ient
to rule out a negative efect of the addition of rIFN-y. The dose intnsty of WFN-a2, for the two treatment
anrs was the same. The addition of rIFN- does not improve the response rate of rIFN42, monotherapy. A
possible detrimental effect cannot be exdudedL
Keywwr_ renal cell cio; interferon alpha; interferon gamma.
Patients with renal cell carcinoma (RCC) currently have few
therapeutic options once the disease has become metastastic.
Appro tely 25% of such patients have metastatic disease
at the time of first presentation (Ritchie et al., 1983). The
median survival for these patients is, independent of treat-
ment, 6-12 months (De Forges et al., 1988). Spontaneous
regression of metastases after tumour nephrectomy occurs in
less than 1% (Montie, 1977). Treatment with hormones and
chemotherapy, both single agent and combination, has no
proven impact on survival (Harris et al., 1983; Yagoda and
Bander, 1989). Several forms of immunotherapy have been
applied, resulting in a limited number of sotimes durable
responses (McCune, 1983). Interferon-alpha (EFN-a) is most
extensively used in the treatment of advanced RCC, both the
natural and recombinat(r) forms. Most studies have pro-
vided evidence for modest but reproducible anti-tumour
activity in advanced RCC (Goldstein and Laslo, 1986;
Krown, 1987; Sarna et al., 1987; Muss, 1988, Buzaid and
Todo, 1989; Horoszewski and Murphy, 1989). The response
rates recorded from adequate trials (i.e. more than 20 eligeibl
patients and a dose of IFN-a of more than 3 x 10'U day-',
n = 431) vary from 5 to 26% (mean 17%; 2% CR and 15%
PR).
Experience with rIFN-'y in renal cell carcnoma is limited
and, with a few exceptions, disappointing (Rinehart et al.,
1986; Quesada et al., 1987; Gamick et al., 1988; Otto et al.,
1988; Aulitzky et al., 1989; Bruntsch et al., 1990). Little
information is available about the optimal dose, schedule and
route of IFN-'y administration.
Modification of the host response is frequently restricted to
a narrow dose range, and in a recent study optimal modula-
tion by rIFN-y has been found in the low dose range
(100 pgm-) (Maluish et al., 1988). Against this background,
the findings of Aulitzky et al. (1989) are interesting. They
observed a 30% response rate (two CRs, four PRs) in 16
patients treated with lOO1g IFN-y (Genentech) s.c. once a
week.
The combination of IFN-a and IFN--y has ben explored on
the basis of in vitro observations indicating a synergism
between rIFN-y and rIFN-a (Czarnieci et al., 1984; Hubbell
et al., 1987). The results published so far are, however,
disappointing (Kurzrock et al., 1986; Foon et al., 1988;
Quesada et al., 1988; Ernstoff et al., 1990). De Mulder and
co-workers (Geboers et al., 1988; De Mukler et al., 1990)
studied the efficacy of the combination of an escalating dose
rEFN-a;z, (6pgm-2=2x10Um2 staring dose) and a
fixed low dose of rIFN- (100 g m-2 = 2 x 10'm-) twice
weekly subcutaneously in patients with advanced progresive
renal cell carcinoma. The overall response rate was 26% (two
CRs, six PRs). The maximal tolerated dose of IFN-x2, was
30 gm 2 (6-36 pg m-). The feasibility and efficacy of this
approach was proven in the tratment of a second cohort of
patients (De Mulder et al., 1991). In view of these data, an
EORTC randomised study was initiated to determine if the
addition of rIFN-y has any impact on the response rate and
survival of patients with advanced metastatic renal cell car-
cinoma.
P and ho-
Trial design
The study was designed as a randomised phase Ill trial with
an interim analysis planed after data for 40 eligible patients
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were available in each arm in order to ensure that continu-
ation of the trial was ethical. After checking all eligibility
criteria, the randomisation was centrally performed at the
EORTC Data Center. Patients were stratified according to
institution and performance status. The study was performed
according to good clinical practice guidelines, which included
the verification of all items given on the forms with the
source documents. The main end points of the study were the
comparison of the two treatments arms regarding response
rate, time to response, response duration, survival and
tolerance.
Patient population
Patients with histologically proven renal cell carcinoma with
metastatic measurable or evaluable disease were considered
for the study if they met the following critena: age 18-75
years; no prior chemo- and or immunotherapy; prior hor-
monal treatment was allowed; there should have been proven
progression, espeially after a recent nephrectomy-, World
Health Organization (WHO) performance status 0-1; ade-
quate haematological status, renal and liver function; normal
serum calcium level; no concurrent serious medical ilness
(active infections, significant cardiac disease) or second
malignanci except adequately treated basal cell carcnoma
of the skin or cone biopsied carcinoma in situ of the cervix;
no history of sizure disorders or signs of central nervous
system metastases; life expectancy of at least 3 months;
absence of a lipoprotein disorder. Concomitant medication
with corticosteroids or vasodilators was not allowed. All
patients gave their written or witnessed informed consent.
Treatment regimen
rIFN-ak and rIFN-y (Genentech) were supplied by Boeh-
ringer Ingelheim (Alkmaar, The Netherlands) and provided
as a sterile lyophilsed powder. The powder contained 15 jig
of IFN-a2 with a degree of purity of >98% and a specific
activity of 4.4xIO6IUl5 ig- based on the NIH IFN-x
standard GO-23-901-527 for rIFN-x or 150Mg of IFN-'y with
a specific activity of 2 x I0' IU mg-' protein, based on the
NIH IFN-'y standard Gg23-901-350. The freeze-dried prepar-
ations were reconstituted with 1 ml of sterile water immedi-
ately before use to yield rIFN-a2c and rIFN-7 concentrations
of S x 106 IU ml[' and 10 x 106 IU ml' respectively
Injections were given subcuteneously twice a week on an
out-patient basis, although it was recommended that the first
injection be given during a brief stay in hospital. Treatment
arm A consisted of rIFN-a2 monotherapy and arm B con-
sisted of the same dose of rIFN-zk plus rIFN-y. rIFN-7 was
given at a dose of 100 jg m-2 (2 x 106 IU m-) and rIFN-a2c
was given at a dose of 30 igm-2 (10 x 106IU m-). In arm
B the two IFNs were given at the same time at two different
sites. In the case of WHO grade III-IV toxicity, treatment
was discontinued until recovery, with a maximum delay in
treatment of 14 days. In case of recovery, IFN treatment was
to be restarted with a reduction of the dose of rIFN-a2c of
6 jig m2. If a dose reduction resulted in a dose below
12 igm-2 the patient went off study. In case of grade II
hamantological toxicity, this was followed every 2 weeks until
stabilisation was observed.
Acetaminophen (500 mg) was routinely prescribed to
alleviate side-effects. This treatment was started 4 h before
the IFN injection and continued for 24-48 h thereafter.
Pretreatment andfollow-up examinations
Pre-study evaluations included full medical history and
physical examination, tumour measurements, electrocardio-
gram, chest radiograph, white blood cell count, platelets and
a complete chemistry profile. Four-weekly monitoring in-
cluded side-effects according to the WHO grading system,
haematological status, urine analyses and biochemical
measures: creatinine, alkaline phosphatase, aspartate amino-
transferase, alanine aminotransferase, lactate dehydrogenase,
bilirubin, and gamma-glutamyl transferase. Total protein and
subfractions, cholesterol, triglycerides and interferon
antibodies were monitored every 4 weeks. Electrocardio-
graphy was repeated when indicated. Tumours were
measured every 4 weeks with standard radiographic, com-
puterised tomographic or ultrasonographic techniques as ap-
propriate.
Evaluation criteria
The criteria for measurability of disease were according to
the EORTC Data Center procedures manual (van Oosterom
et al., 1993). Nodes smaller than 2 cm and liver metastases
smaller than 3 cm in diameter were not considered to be
measurable or evaluable. Complete remission (CR) was
defined as the disappearance of all clinical evidence of
tumour for a minimum of 4 weeks. Partial remission (PR)
was defined as a 50% or greater decrease in the sum of the
products of the perpendicular diameters of all measurable
lesions, without simultaneous increase in the size of any
excising lesion or development of new lesions, for a minimum
of4 weeks. Progressive disease (PD) was defined as a 25% or
greater increase in the size of at least one existing lesion or
the appearance of new lesions. SD was defined as a decrease
of less than 50% or an increase of less than 25%. For CR
and PR duration of response was measured from the day of
the start of treatment until disease progression or death. A
patient was evaluable for toxicity when at least 4 weeks'
treatment was given. A patient was evaluable for response
when at least 8 weeks treatment was completed. However, all
patients with PD, irrespective of the duration of treatment,
were included in the response analysis. In case of stable
disease treatment was to be discontinued after 6 months.
When a PR or CR was seen treatment was to be continued
to 1 year from the date of CR/PR.
Statistical methods
The expected response rate for the combination arm was
25-30%; the expected response rate for the monotherapy
arm was between 15% and 20%. The iinimal difference in
response rate which was of practical interest was defined to
be 15%. To detect such a difference at error rates z=0.05
and P = 0.20, 94 eligible and evaluable patients were required
on each treatment. In order to ensure that continuation of
the trial was ethical, an interum analysis was planned after
receipt of the data for the first 40 patients in each arm. The
response rates were compared using a two-sided Fisher exact
test. The duration of response and the duration of survival
were estimated by the Kaplan-Meier technique and com-
pared using a two-sided log-rank test.
Resits
Between November 1988 and September 1990, 102 patients
entered the study and were randomly assigned to treatment
as follows: arm A, 54 patients; arm B, 48 patients. Four
patients were ineligible, one on treatment A and three on
treatment B: one patient had a second primary, one patient
had no evaluable lesions and two patients started within 4
weeks after tumour nephrectomy without documented pro-
gression of metastatic disease. Nine eligible patients were not
evaluable for response.
Patient characteristics at entry are depicted in Table I and
are well balanced in the two treatment groups. For the entire
group, 68% were male and 43% had a WHO performance
status of 0. Eighteen per cent of the patients started treat-
ment with the primary tumour in situ. Prior radiotherapy,
mainly on threatening bone lesions, was given in 10% of the
patients. Lung metastases were present in almost all patients.
In 27% lung was the only site of disease. Liver metastases
alone or in combination with other sites were seen in 14%.
The majority of the patients had only one or two sites of
disease (76%).
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9Table I Patient characteristics at entry
IFN-I IFN-Z + IFN-y
No. of patients (n = 102) 54 48
Not eligible 1 3
Male-female 37:17 32:16
Median age (range) 55 (27-75) 58 (32-74)
Performance status
WHO 0 20Y 23
WHO 1 33 25
Prior treatment (n = 98)
Nephrectomy 42 38
No nephrectomy 11 7
Radiotherapy 8 2
Hormonal treatment 0 1
Site of disease
Lungs only 14 14
Lungs + primary 4 3
Lungs + nodes 3 4
Lungs + liver 3 3
Lungs + others 7 9
Liver + others 5 3
Number of sites
1 17 19
2 19 23
3-6 16 9
>5 0 1
Not evaluable for response 6 7
'Missing information for one patient.
FNg WIFNy inRFCC
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Table n Response to treatment in eligible patients
rIFN-a2, rIFN-.2 + IFN-y
CR 1 0
pCR 1 1
PR 5 1
SD 19 19
PD 22 20
Early death 2 3
Unknown 3 1
Total 53 45
Response rate 130o 4% (P =0.17)
There were four mixed responses on monotherapy and three mixed
responses on the combination which are included in the Table as PD.
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Number of patients at risk
52 15 8 4
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2 2 1 1 0 IFN-a
2 1 1 1 1 IFN-a+ IFN-y
Treatment efficacy
Considering all eligible patients (98) entered into the trial, the
response rates were as follows: rIFN-ac,2 monotherapy, one
CR, one pathological CR, five PRs and 19 no change (NC),
overall 13%; rIFN-a + rIFN-y, one pathological CR, one
PR and 19 NC, overall 4% (Table II). This difference was
not statistically significant at P = 0.17 in favour of arm A. If
a relevant difference in favour of the combination arm were
10% and the expected response on the monotherapy were
15%, the probability of missing this difference with the
observed results would be 0.001. Although the difference was
not statistically significant, the numbers are inadequate to
show true equivalence or to exclude a potential negative
effect of the addition of interferon-y. however this was not
the purpose of our study. A mi'xed response was seen in four
out of 53 patients in arm A and three out of 45 in arm B.
The median time to response among responders was 114 days
(range 59-301 days) and the median response duration was
60 weeks, with seven of the nine responders having pro-
gressed. Based on an average follow-up of 1 year, the overall
median survival was 43 weeks in arm A and 34 weeks in arm
B (P = 0.73) (Figure 1). The time to progression is given in
Figure 2. When the patients with their primary in situ are
excluded, the observed response rate was 7/42 (17%) for
treatment arm A and 2/38 (5%) for arm B. The characteris-
tics of all responding patients are shown in Table III. Six out
of nine responded in the lungs, however only in two patients
was this the only site of disease. In two patients concomitant
metastases in the liver disappeared during therapy. The sites
with unmeasurable disease remained clinically unchanged.
Two patients had cytological proof of renal cell carcinoma in
the enlarged node prior to the start of treatment. After
discontinuation of treatment lymph node dissection was per-
formed. Pathological examination revealed no tumour and
the patients are therefore considered as having a pathological
CR.
One possible explanation for the lack of response in the
combination arm could be a difference in the dose intensity
ofrIFN-w. in the two groups. However, dose intensity, dose
reductions and delays were similar in the two arms. In both
arms 90% of the patients received 100% of the intended dose
of rIFN-2.
Figre 1 Time to progression.
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36 42
Number of patients at risk
52 29 14 7
45 23 10 5
(months)
4 2 1 1 o IFN-a
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Fgue 2 Duration of surVival.
Toxicity
Observed grade II and III toxicity is given in Table IV.
Side-effects were those known to be associated with
interferon treatment. The vast majority of the patients
developed fever. anorexia, fatigue and to a lesser extent
flu-like symptoms. There was no difference between the two
treatment groups. One patient deveioped a WHO grade III
thrombocytopenia, but fully recovered after discontinuation
of treatment. The white blood count (WBC) was only mar-
ginally influenced, although in the combination arm three
patients developed reversible WHO grade III leucopenia.
Discsson
There is no doubt that interferons can induce responses in
advanced renal cell carcinoma. The response percentage
4FN-a and FN7 inRAC
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Table M Characteristics of responding patients
Age Sex PS Site Si-e Response Comment Response duration (weeks
1 61 M I Lung 22 x 19 PR PD in lungs and nodes, brain metastases. 102
Dead due to malignant disease
Liver 10 x 10 CR
2 41 M 0 Lung 23 x 22 CR PD supraclavicular node. CDF after lymph 68
Local 29 x 29 CR node dissection
3 49 M 1 Nodes 30 x 35 PR PD lungs, brain metastases. Dead due 45
to malignant disease
4 46 M 0 Nodes 30 x 25 pCR No vital tumour at surgery 192 +
5 53 F I Lung 15 x 10 PR PD initial sites. Dead due to malignant 21
15 x 15 disease
Bone 40 x 20 NC
6 55 M 1 Lung 20 x 11 CR PD lungs. After metastasectomy NED. 91
13 x 16 Brain metastases. After RT alive
8x9 PR
Liver 40 x 40
62 x 59 NC
Bone Irradiated
7 66 F 0 Lung 49 x 23 PR PD brain metastases. Death due to 52
6 x 6 malignant disease
15 x 12
17 x 16
17 x 17
8 65 M 0 Lung 23 x 20 PR PD initial sites. Dead due to malignant 43
15 x 13 disease
18 x 15
20 x 18
9 66 F 0 Nodes 25 x 40 CR After surgery only fibrosis and non-vital 211 +
tumour was seen (necrosis)
CDF, continuously disease free; NED, no evidence of disease; RT, radiotherapy.
Table IV Toxicity (WHO grade)
rIFN-2,7 rIFN-a + IFN-y
11 III II III
Platelets 1 1 0 0
WBC 7 0 6 3
Pulmonary 4 2 0 1
Fever 27 9 24 9
Cutaneous 2 0 3 0
Alopecia I 0 3 0
Cardiac (rhythm) 4 1 4 0
Mucous I 0 2 0
Nausea and vomiting 11 5 9 5
Neurotoxicity 0 0 0 1
Non-WHO 2-3 2-3
Flu-like syndrome 16 16
Anorexia 21 19
Mood alterations 8 6
Fatigue 27 24
Headache 5 8
II, moderate, III. severe.
obtained from pooled data is about 17% (Krown, 1987;
Muss, 1988; Horoszewicz et al., 1989; De Mulder et al.,
1991). Prognostic factors such as performance status, tumour
volume, presence of bone metastases and disease-free interval
are well recognised and are the main explanation for the
variation in response observed in the various studies. There is
no indication that the route of administration, schedule or
the type of IFN-a is critical for the observed clinical results.
Dose dependency is suggested but an adequate randomised
study to address this question has never been performed.
Very low daily dosages, i.e. below 2 x 10' IU daily, are prob-
ably ineffective. Our own observation in a small group of
patients corroborates this experience (Geboers et al., 1988).
In the present multicentre study the activity of IFN-a is
confirmed with an overall response rate of 13%. When only
patients without their primary tumour are analysed, the re-
sponse rate is 17%, which is consistent with the range
observed in the literature. One should realise that these
results were obtained with a relatively low dose of IFN-a
(10 x 106IU m-) and a twice-weekly schedule, again an
indication that the regimen is not critical and that IFN-x
given above a certain threshold is able to induce responses in
sensitive tumours. A remarkable finding was that in two
patients an objective response in the liver was seen.
The main purpose of the study was to study the relevance
of the addition of IFN-y, which was based both on labora-
tory observations as well as on the results of earlier studies.
The results were very disappointing because only in two
patients (4%) was an objective response observed and the
study, initially planned as a randomised phase III study, was
stopped after an interim analysis. As indicated before, the
probability of obtaining these results if a difference of 10% in
favour of the combination was actually present is extremely
low. Equivalence in outcome or even the inverse outcome,
i.e. a potential adverse effect of the combination, cannot be
excluded with adequate power in view of the numbers in-
volved, but this was not the purpose of the study. There is no
satisfactory explanation for this result. Patient characteristics
of the two patient populations were similar and the likeli-
hood that this observation could have been made by chance
is almost negligible. The mechanisms of action of IFN-x are
very pleiotropic, and many mechanisms can be responsible
for the observed anti-tumour effect. There are actions directly
on the tumour such as an antiproliferative effect, and there
are indications that the induction of 2',5'-oligoadenylate syn-
thetase is related with this potential (Grander et al., 1990).
On the other hand, immunological properties such as the
induction of natural killer activity and the enhancement of
the expression of antigens on the tumour might play a role.
The mechanism of action as elucidated in hairy cell
leukaemia (Vedantham et al., 1992), the carcinoid (Grander
et al., 1990) and the observation that the addition of 20 mg
of prednisone had no impact on the anti-tumour effect
(Fossa et al., 1990) suggest a direct effect on the tumour cell.
Interferon-gamma is considered a true immunomodulating
agent, predominantly on macrophages. with few direct anti-
proliferative effects on tumour cells. The results with IFN-y
374IN-zand IFN- in RCC
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monotherapy are generally disappointing. The 30% response
rate observed by Aulitzky et al. (1989), so far unconfirmed.
applying an individually tailored dose of IFN-y based on
parameters of immune stimulation such as neopterin excre-
tion. indicates the sensitivity of this disease depending on
very specific requirements. The IFN-y dose used in the pre-
sent study was within the same range. One of the explana-
tions of the generally low response rate in combination
studies could be the relatively low dose of IFN- given in
these studies (De Mulder et al., 1991). In the present study
this explanation is unlikely in view of the almost identical
dose intensity of IFN-2c in the two treatment arms.
Based on these results, the combination of IFN-a and
IFN-y in the dose and schedule described in this study can-
not be recommended. Our results confirm the limited activity
of IFN-a monotherapy in this disease.
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